Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Anesthesiology and Pain Medicine
  4. Articles

  5. The Basic Study of the Mechanism of Propofol-Related Infusion Syndrome Using a Murine Skeletal Muscle Injury Model
  6. Scopus by Title (Ref)

Anesthesiology and Pain Medicine

Home
Current IssueAll IssuesIn PressAccepted ManuscriptsSearch
Instructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Protocol for in vitro differentiation of C2C12 myoblasts into mature myotubes

- Oh J.M. , et al.

2. Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database

- Balzano N. , et al.

3. Developing In Vitro Models to Define the Role of Direct Mitochondrial Toxicity in Frequently Reported Drug-Induced Rhabdomyolysis

- Bin Dayel F.F. , et al.

4. Ginsenoside Rg3 protects glucocorticoid-induced muscle atrophy in vitro through improving mitochondrial biogenesis and myotube growth

- Kim R. , et al.

5. The Influence of Analgesic Modalities on Postoperative Cancer Recurrence

- Edinoff A.N. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.